N.Y. jury holds drug firm liable in opioid crisis

Teva Pharmaceuticals was the only manufacturing defendant left in the lawsuit after other parties settled


By JENNIFER PELTZ
Associated Press

NEW YORK — A jury held Teva Pharmaceuticals responsible for contributing to the opioid crisis, delivering one of few verdicts so far among thousands of lawsuits nationwide over the painkillers, New York's attorney general said Thursday. 

Attorney General Letitia James' office said the Suffolk County jury found the drug company played a role in furthering what is legally termed a public nuisance but had lethal consequences — an opioid use epidemic linked to more than 500,000 deaths in the U.S. in the past two decades. 

Trucks drive in front of Teva Pharmaceutical Logistic Center in the town of Shoam, Israel, Oct. 16, 2013.
Trucks drive in front of Teva Pharmaceutical Logistic Center in the town of Shoam, Israel, Oct. 16, 2013. (File photo/Dan Balilty/Associated Press)

"Teva Pharmaceuticals USA and others misled the American people about the true dangers of opioids," James, a Democrat, said in a news release. "Today, we took a significant step in righting the wrongs this country has collectively experienced over the last two decades."

Messages seeking comment were sent to a lawyer for Teva and to the judge's staff.

A separate trial will follow to determine what penalty Teva will face, James said. 

Around the country, state and local governments, Native American tribes, unions, school districts and others have taken on the drug industry in lawsuits over the powerful painkillers

New York's lawsuit, filed in 2019, targeted several opioid producers and distributors, companies that buy medications in bulk and sell them to pharmacies. Among the defendants were OxyContin maker Purdue Pharma and members of the billionaire family that controls it. 

The suit accused drug companies of breaching their legal duties "to profiteer from the plague they knew would be unleashed." The state said that drug manufacturers collaborated to mislead people and downplay the serious risks of opioid addiction, and that drug distributors skirted systems meant to limit orders for painkillers. 

New York said the companies' conduct cost the state hundreds of millions of dollars in addiction treatment bills and other expenses. 

Teva was the sole manufacturing defendant left in the suit after other parties settled, most recently  Allergan Finance LLC in December. The various settlements have netted New York up to $1.5 billion. 
The trial started months ago. The jury began deliberating Dec. 14, taking some days off for Christmas. 

Teva and the regional drug distribution company Anda were also defendants in a Suffolk County lawsuit. 
Elsewhere, only a few opioid cases have gone to verdicts to date, with no clear consensus on outcomes.
An Oklahoma judge ruled against drugmaker Johnson & Johnson in 2019, but the state's supreme court overturned that decision  in November. 

A California judge in November ruled in favor of drugmakers, and a federal jury in Cleveland sided with two Ohio county governments  that had claims against pharmacy chains. 

A trial has been completed but a judge has not yet ruled in a West Virginia case, and a trial is ongoing in Washington state. Thousands of other cases are in the process of heading to trial.

There have also been settlements. Some of the biggest industry names — such as distributors AmerisourceBergen, Cardinal Health and McKesson and drugmakers Johnson & Johnson, Mallinckrodt Pharmaceuticals — have reached nationwide settlements with a cumulative value potentially well over $30 billion. Most of the money is being directed to fight the epidemic. 

But most of those deals have not been finalized, and there has been one very big reversal. In mid-December, a federal judge rejected OxyContin maker Purdue Pharma's sweeping deal to settle thousands of lawsuits over the toll of opioids.

___

Associated Press writer Deepti Hajela contributed to this report. 
 

Recommended for you

Join the discussion

The EMS news & trends you need, delivered right to your inbox.

Thanks! You've been successfully signed up for the EMS1 Daily

Copyright © 2022 EMS1. All rights reserved.